[1]汪六林,李刚,刘祺,等.大黄素调节消皮素蛋白E通路的细胞焦亡改善UUO小鼠肾脏纤维化的机制研究[J].陕西中医,2026,(3):291-296.[doi:DOI:10.3969/j.issn.1000-7369.2026.03.001]
　WANG Liulin,LI Gang,LIU Qi,et al.Study on the mechanism of emodin regulating GSDME pathway-induced pyroptosis to improve renal fibrosis in UUO mice[J].,2026,(3):291-296.[doi:DOI:10.3969/j.issn.1000-7369.2026.03.001]
点击复制

大黄素调节消皮素蛋白E通路的细胞焦亡改善UUO小鼠肾脏纤维化的机制研究

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2026年3期
页码:
291-296
栏目:
出版日期:
2026-03-05

文章信息/Info

Title:
Study on the mechanism of emodin regulating GSDME pathway-induced pyroptosis to improve renal fibrosis in UUO mice
作者:
汪六林1; 2; 3; 4; 李刚1; 2; 3; 4; 刘祺1; 2; 3; 4; 王瑞1; 2; 3; 4; 王紫琳1; 2; 3; 4; 崔梦迪5; 金善善1; 2; 3; 4; 5
（1.湖北省中医院，湖北 武汉 430063；2.中医肝肾研究及应用湖北省重点实验室,湖北中医药大学附属医院，湖北 武汉 430063；3.湖北时珍实验室，湖北 武汉 430063；4.湖北省中医药研究院，湖北 武汉 430063；5.湖北中医药大学，湖北 武汉 430061）
Author(s):
WANG Liulin1; 2; 3; 4; LI Gang1; 2; 3; 4; LIU Qi1; 2; 3; 4; WANG Rui1; 2; 3; 4; WANG Zilin1; 2; 3; 4; CUI Mengdi5; JIN Shanshan1; 2; 3; 4; 5
（1.Hubei Provincial Hospital of Traditional Chinese Medicine,Wuhan 430063,China;2.Hubei Key Laboratory of Theory and Application Research of Liver and Kidney in Traditional Chinese Medicine,Affiliated Hospital of Hubei University of Chinese Medicine,Wuhan 430063,China;3.Hubei Shizhen Laboratory,Wuhan 430063,China;4.Hubei Province Academy of Traditional Chinese Medicine,Wuhan 430063,China;5.Hubei University of Chinese Medicine,Wuhan 430061,China）
关键词:
慢性肾脏病; 大黄素; 肾纤维化; 炎症因子; 细胞焦亡; 消皮素蛋白E
Keywords:
Chronic kidney disease; Emodin; Renal fibrosis; Inflammatory factor; Pyroptosis; Gasdermin E
分类号:
R 692.9
DOI:
DOI:10.3969/j.issn.1000-7369.2026.03.001
文献标志码:
A
摘要:
目的：探讨大黄素对慢性肾脏病（CKD）肾脏纤维化的干预作用及消皮素蛋白E（GSDME）介导的细胞焦亡的影响。方法：将雄性C57BL6小鼠按计算机生成的随机数随机分为假手术组(Sham组)、单侧输尿管梗阻模型组(UUO 组)和大黄素中药干预UUO 组(大黄素组)，每组8只。干预结束后进行小鼠肾功能中血尿素氮、血肌酐和血尿酸的检测，肾组织病理损伤检测，酶联免疫吸附测定（ELISA）检测炎症因子白细胞介素（IL）-1β和IL-18，TUNEL染色观察肾组织细胞凋亡，Western blot分析肾组织细胞焦亡相关蛋白半胱氨酸天冬氨酸蛋白酶（Caspase）-3、GSDME-N 和 GSDME-FL，纤维化相关蛋白胶原蛋白（Collagen）Ⅰ、α-平滑肌肌动蛋白（SMA）的变化。结果：构建UUO模型小鼠，结果发现大黄素能有效改善小鼠肾功能，减轻肾组织病理损伤，降低炎症因子表达，减轻细胞凋亡，抑制纤维化的生成，并通过调控GSDME介导的细胞焦亡途径发挥作用。结论：大黄素可能通过调控GSDME介导的细胞焦亡途径减轻炎症因子的表达，改善肾脏纤维化。
Abstract:
Objective:To explore the intervention effect of emodin on renal fibrosis in chronic kidney disease (CKD) and its influence on gasdermin E (GSDME)-mediated pyroptosis.Methods:The male C57BL6 mice were randomly divided into the sham operation group (Sham group),the unilateral ureteral obstruction model group (UUO group),and the rhodanine-based traditional Chinese medicine intervention group for UUO (rhodanine group) according to the randomly generated numbers by the computer,with 8 mice in each group.After intervention,the renal function of mice (blood urea nitrogen,serum creatinine and blood uric acid) was detected,renal tissue pathological damage was examined,inflammatory factors (IL-1β and IL-18) were detected by ELISA,apoptosis of renal tissue cells was observed by TUNEL staining,and the changes of pyroptosis-related proteins Caspase-3,GSDME-N and GSDME-FL,fibrosis-related proteins CollagenⅠand α-SMA in renal tissue cells were analyzed by Western blot.Results:The UUO model mice were successfully constructed.It was found that emodin could effectively improve the renal function of mice,reduce renal tissue pathological damage,lower the expression of inflammatory factors,alleviate cell apoptosis,and inhibit the formation of fibrosis,and exert its effect through regulating the GSDME-mediated pyroptosis pathway.Conclusion:Emodin may alleviate the expression of inflammatory factors and improve renal fibrosis by regulating the GSDME-mediated pyroptosis pathway.

参考文献/References:

[1]NAVANEETHAN S D,BANSAL N,CAVANAUGH K L,et al.KDOQI US commentary on the KDIGO 2024 clinical practice guideline for the evaluation and management of CKD[J].Am J Kidney Dis,2025,85(2):135-176.
[2]WANG L,XU X,ZHANG M,et al.Prevalence of chronic kidney disease in China:Results from the sixth China chronic disease and risk factor surveillance[J].JAMA Intern Med,2023,183(4):298-310.
[3]GRAMS M E,MELAMED M L.Chronic kidney disease[J].Ann Intern Med,2025,178(9):ITC129-ITC144.
[4]KLINKHAMMER B M,BOOR P.Kidney fibrosis:Emerging diagnostic and therapeutic strategies[J].Mol Aspects Med,2023,93:101206.
[5]DING Z,DA H H,OSAMA A,et al.Emodin ameliorates antioxidant capacity and exerts neuroprotective effect via PKM2-mediated Nrf2 transactivation[J].Food Chem Toxicol,2022,160:112790.
[6]XIE R M,LI S.Emodin weakens liver inflammatory injury triggered by lipopolysaccharide through elevating microRNA-145 in vitro and in vivo[J].Artif Cells Nanomed Biotechnol,2019,47(1):1877-1887.
[7]SHEN Z,ZHAO L,YOO S,et al.Emodin induces ferroptosis in colorectal cancer through NCOA4-mediated ferritinophagy and NF-kappab pathway inactivation[J].Apoptosis,2024,29(9-10):1810-1823.
[8]WANG L,WANG X,LI G,et al.Emodin ameliorates renal injury and fibrosis via regulating the miR-490-3p/HMGA2 axis[J].Front Pharmacol,2023,14:1042093.
[9]KETELUT-CARNEIRO N,FITZGERALD K A.Apoptosis,pyroptosis,and necroptosis-oh my! the many ways a cell can die[J].J Mol Biol,2022,434(4):167378.
[10]WANG Y,GAO W,SHI X,et al.Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin[J].Nature,2017,547(7661):99-103.
[11]ZHANG Z,ZHANG Y,XIA S,et al.Gasdermin E suppresses tumour growth by activating anti-tumour immunity[J].Nature,2020,579(7799):415-420.
[12]LI Y,YUAN Y,HUANG Z,et al.GSDME-mediated pyroptosis promotes inflammation and fibrosis in obstructive nephropathy[J].Cell Death Differ,2021,28(8):2333-2350.
[13]SHEN X,WANG H,WENG C,et al.Caspase 3/GSDME-dependent pyroptosis contributes to chemotherapy drug-induced nephrotoxicity[J].Cell Death Dis,2021,12(2):186.
[14]LI Y,YU X,SHANG X,et al.Biochanin a suppresses Klf6-mediated Smad3 transcription to attenuate renal fibrosis in UUO mice[J].Phytomedicine,2024,135:156067.
[15]HUANG R,FU P,MA L.Kidney fibrosis:From mechanisms to therapeutic medicines[J].Signal Transduct Target Ther,2023,8(1):129.
[16]柳小远,付荣国,于小勇,等.益血降浊法调节TGF-β1/Smad信号通路以改善肾纤维化的实验研究[J].陕西中医,2025,46(9):1155-1159.
[17]WEI X,HOU Y,LONG M,et al.Advances in energy metabolism in renal fibrosis[J].Life Sci,2023,312:121033.
[18]ROCCATELLO D,LAN H,SCIASCIA S,et al.From inflammation to renal fibrosis:A one-way road in autoimmunity?[J].Autoimmun Rev,2024,23(4):103466.
[19]田海军,郑艳辉,俞燕.慢性肾脏病微炎症状态及其中医药治疗研究进展[J].中医药临床杂志,2022,34(9):1768-1773.
[20]庞欣欣,王学艺,郑威,等.经方中大黄的配伍在慢性肾脏病治疗中的应用[J].世界中医药,2023,18(5):645-649.
[21]XIONG W,TANG J,YU H,et al.Emodin inhibits M1 macrophage activation that related to acute and chronic kidney injury through EGFR/MAPK pathway[J].Funct Integr Genomics,2024,24(4):131.
[22]MARTINEZ-KLIMOVA E,APARICIO-TREJO O E,GOMEZ-SIERRA T,et al.Mitochondrial dysfunction and endoplasmic reticulum stress in the promotion of fibrosis in obstructive nephropathy induced by unilateral ureteral obstruction[J].Biofactors,2020,46(5):716-733.
[23]FENG L,LIN Z,TANG Z,et al.Emodin improves renal fibrosis in chronic kidney disease by regulating mitochondrial homeostasis through the mediation of peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1alpha)[J].Eur J Histochem,2024,68(2):231-235.
[24]CHEN Y,HAN X,HAO Y,et al.Emodin-induced ERalpha degradation via SYVN1 alleviates vascular calcification by preventing HIF-1alpha deacetylation in chronic kidney disease[J].Phytomedicine,2025,145:156915.
[25]JI J,TAO P,WANG Q,et al.Emodin attenuates diabetic kidney disease by inhibiting ferroptosis via upregulating Nrf2 expression[J].Aging,2023,15(15):7673-7688.
[26]VASUDEVAN S O,BEHL B,RATHINAM V A.Pyroptosis-induced inflammation and tissue damage[J].Semin Immunol,2023,69:101781.
[27]SHI J,ZHAO Y,WANG K,et al.Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death[J].Nature,2015,526(7575):660-665.
[28]姜红.达格列净抑制Caspase-3/GSDME通路介导的肾小管上皮细胞焦亡在糖尿病肾病发病中的作用及机制研究[D].蚌埠：蚌埠医科大学,2025.
[29]王奕潇,王子昊,杨云舒,等.细胞焦亡在糖尿病慢性创面中的表达与作用研究[J].空军军医大学学报,2024,45(8):859-862.
[30]冉珍琴,刘泽慧,杨蓉,等.细胞焦亡在糖尿病肾脏病中的作用及机制研究进展[J].昆明医科大学学报,2026,47(1):148-156.
[31]LI S,FENG L,LI G,et al.GSDME-dependent pyroptosis signaling pathway in diabetic nephropathy[J].Cell Death Discov,2023,9(1):156.
[32]LIU Y,PAN R,OUYANG Y,et al.Pyroptosis in health and disease:Mechanisms,regulation and clinical perspective[J].Signal Transduct Target Ther,2024,9(1):245.

相似文献/References:

[1]屈 凯,王悦彤,王漱非,等.基于文献研究探讨益肾散结法防治肾小球硬化的理论内涵*[J].陕西中医,2019,(7):919.
　QU Kai,WANG Yuetong,WANG Shufei,et al.Based on literature research to explore the theoretical connotation of Kidney-reinforcing and Mass-disintegrating for prevention and treatment of glomerulosclerosis[J].,2019,(3):919.
[2]任永朋,华 琼,刘彦妍,等.中医“治未病”思想在防治肾脏病中的应用*[J].陕西中医,2019,(8):1101.
　REN Yongpeng,HUA Qiong,LIU Yanyan,et al.The application of the thought of “preventive treatment of disease” in the prevention and treatment of kidney disease in traditional Chinese medicine[J].,2019,(3):1101.
[3]张宏强,李桂霞,章彩凤,等.许筠治疗慢性肾病临床药对举隅*[J].陕西中医,2020,(6):808.[doi:DOI:10.3969/j.issn.10007369.2020.06.031]
[4]陈紫薇,陈 明△.从脾论治慢性肾脏病的生物学基础探讨*[J].陕西中医,2020,(11):1627.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
　CHEN Ziwei,CHEN Ming..Discuss the biological foundation for chronic disease therapy from treatment through the spleen[J].,2020,(3):1627.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
[5]董 怡,马 静,余楠楠,等.大黄复方保留灌肠辅助治疗慢性肾脏病疗效及对患者生活质量的影响[J].陕西中医,2021,(7):910.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.026]
　DONG Yi,MA Jing,YU Nannan,et al.Effect analysis of rhubarb compound retention enema adjuvant treatment of chronic kidney disease and its impact on patients' quality of life[J].,2021,(3):910.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.026]
[6]齐 宁,宋姝西,刘香玉,等.参芪延肾方治疗慢性肾脏病疗效及对患者半乳糖缺陷IgA1、晚期糖基化终产物和微炎性反应状态的影响[J].陕西中医,2022,(5):596.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.012]
　QI Ning,SONG Shuxi,LIU Xiangyu,et al.Effects of Shenqi Yanshen recipe on the levels of Gd-IgA1,AGEs and micro inflammatory response in patients with chronic kidney disease[J].,2022,(3):596.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.012]
[7]麦芳雄,张香兰,朱德礼.温肾健脾清化汤辅助治疗脾肾气虚型慢性肾脏病疗效及对患者血清转化生长因子β1、纤维连接蛋白水平的影响[J].陕西中医,2022,(8):1068.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.019]
　MAI Fangxiong,ZHANG Xianglan,ZHU Deli.Clinical efficacy of Wenshen Jianpi Qinghua decoction in the treatment of chronic kidney disease with spleen-kidney qi deficiency and its effect on serum transforming growth factor β1 and fibronectin levels[J].,2022,(3):1068.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.019]
[8]杨淑彬,李 婷,李晓妮,等.不同中药结肠透析模式对慢性肾脏病患者胃肠道症状和营养状态的影响[J].陕西中医,2022,(12):1698.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.010]
　YANG Shubin,LI Ting,LI Xiaoni,et al.Effects of different colon dialysis modes of traditional Chinese medicine on gastrointestinal symptoms and nutritional status in patients with chronic kidney disease[J].,2022,(3):1698.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.010]
[9]陈 曦,董凯旋,周 荣,等.中药调控p38丝裂原活化蛋白激酶/核因子κB通路治疗肾纤维化研究进展[J].陕西中医,2023,(7):980.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.036]
　CHEN Xi,DONG Kaixuan,ZHOU Rong,et al.Research progress of traditional Chinese medicine regulating p38MAPK/NF-κB pathway in treatment of renal fibrosis[J].,2023,(3):980.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.036]
[10]周 林,禹 红,刘毓玲,等.活肾通络方联合依那普利对慢性肾脏病患者纤维化标志物、人附睾蛋白4水平的影响[J].陕西中医,2023,(10):1400.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.014]
　ZHOU Lin,YU Hong,LIU Yuling,et al.Effect of Huoshen Tongluo decoction and enalapril on renal function,fibrosis markers and HE4 levels in patients with chronic renal disease[J].,2023,(3):1400.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.014]

备注/Memo

备注/Memo:
国家自然科学基金资助青年项目（82405273）；湖北省自然科学基金资助青年项目（2023AFB348）；湖北省自然科学基金创新发展联合基金资助重点项目（2025AFD473）；湖北省自然科学基金创新发展联合基金资助培育项目（2025AFD530）；湖北省自然科学基金联合基金资助项目（2024AFD300）
更新日期/Last Update: 2026-03-05